These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 15704674)
21. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles. Sundbäck M; Douagi I; Dayaraj C; Forsell MN; Nordström EK; McInerney GM; Spångberg K; Tjäder L; Bonin E; Sundström M; Liljeström P; Karlsson Hedestam GB Virology; 2005 Oct; 341(2):190-202. PubMed ID: 16098555 [TBL] [Abstract][Full Text] [Related]
22. Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy. Babudieri S; Longo B; Sarmati L; Starnini G; Dori L; Suligoi B; Carbonara S; Monarca R; Quercia G; Florenzano G; Novati S; Sardu A; Iovinella V; Casti A; Romano A; Uccella I; Maida I; Brunetti B; Mura MS; Andreoni M; Rezza G J Med Virol; 2005 Jul; 76(3):311-7. PubMed ID: 15902712 [TBL] [Abstract][Full Text] [Related]
23. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. Rockstroh JK; Bhagani S; Benhamou Y; Bruno R; Mauss S; Peters L; Puoti M; Soriano V; Tural C; HIV Med; 2008 Feb; 9(2):82-8. PubMed ID: 18257771 [TBL] [Abstract][Full Text] [Related]
24. The prospects for vaccines against HIV-1: more than a field of long-term nonprogression? Sheppard N; Sattentau Q Expert Rev Mol Med; 2005 Feb; 7(2):1-21. PubMed ID: 15710051 [TBL] [Abstract][Full Text] [Related]
25. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users. Devi KhS; Brajachand N; Singh HL; Singh YM J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404 [TBL] [Abstract][Full Text] [Related]
26. Fc receptor but not complement binding is important in antibody protection against HIV. Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298 [TBL] [Abstract][Full Text] [Related]
27. Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India. Kumar S; Aggarwal P; Vajpayee M; Pandey RM; Seth P Vaccine; 2006 Mar; 24(14):2585-93. PubMed ID: 16480792 [TBL] [Abstract][Full Text] [Related]
28. Population effects of preventive and therapeutic HIV vaccines in early- and late-stage epidemics. Owens DK; Edwards DM; Shachter RD AIDS; 1998 Jun; 12(9):1057-66. PubMed ID: 9662203 [TBL] [Abstract][Full Text] [Related]
29. Risks of seroconversion of hepatitis B, hepatitis C and human immunodeficiency viruses in children with multitransfused thalassaemia major. Lee WS; Teh CM; Chan LL J Paediatr Child Health; 2005; 41(5-6):265-8. PubMed ID: 15953326 [TBL] [Abstract][Full Text] [Related]
30. A safe, effective and affordable HIV vaccine--an urgent global need. Joseph J; Etcheverry F; Alcami J; María GJ AIDS Rev; 2005; 7(3):131-8. PubMed ID: 16302460 [TBL] [Abstract][Full Text] [Related]
31. Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines. Koff WC; Russell ND; Walport M; Feinberg MB; Shiver JW; Karim SA; Walker BD; McGlynn MG; Nweneka CV; Nabel GJ Vaccine; 2013 Apr; 31 Suppl 2():B204-8. PubMed ID: 23598483 [TBL] [Abstract][Full Text] [Related]
32. Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients. Kumar R; Singla V; Kacharya Sk Trop Gastroenterol; 2008; 29(3):136-47. PubMed ID: 19115605 [TBL] [Abstract][Full Text] [Related]
33. Seroprevalence of six different viruses among pregnant women and blood donors in rural and urban Burkina Faso: A comparative analysis. Collenberg E; Ouedraogo T; Ganamé J; Fickenscher H; Kynast-Wolf G; Becher H; Kouyaté B; Kräusslich HG; Sangaré L; Tebit DM J Med Virol; 2006 May; 78(5):683-92. PubMed ID: 16555290 [TBL] [Abstract][Full Text] [Related]
34. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis. Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948 [TBL] [Abstract][Full Text] [Related]
35. Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis. Martín-Carbonero L; Barreiro P; Jiménez-Galán G; García-Berriguete R; Núñez M; Ríos P; González-Lahoz J; Soriano V J Viral Hepat; 2007 Jun; 14(6):392-5. PubMed ID: 17501759 [TBL] [Abstract][Full Text] [Related]
36. Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels. Assal A; Barlet V; Deschaseaux M; Dupont I; Gallian P; Guitton C; Morel P; van Drimmelen H; David B; Lelie N; De Micco P Transfusion; 2009 Feb; 49(2):301-10. PubMed ID: 19389212 [TBL] [Abstract][Full Text] [Related]
37. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
38. [Therapeutic and preventive vaccine against HIV problems and the necessity to develop one]. García F Rev Enferm; 2005 Dec; 28(12):24-8. PubMed ID: 16459877 [TBL] [Abstract][Full Text] [Related]
39. HIV vaccine development. Johnston MI Dev Biol (Basel); 2002; 110():57-63. PubMed ID: 12477307 [TBL] [Abstract][Full Text] [Related]
40. Therapeutic immunization strategies for the control of HIV-1. Dorrell L Expert Rev Vaccines; 2005 Aug; 4(4):513-20. PubMed ID: 16117708 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]